Innovage Holding Corp.
InnovAge Holding Corp. (INNV) provides comprehensive medical and support services to seniors, enabling them to live independently through its Program of All-Inc
InnovAge Holding Corp. (INNV) provides comprehensive medical and support services to seniors, enabling them to live independently through its Program of All-Inclusive Care for the Elderly (PACE). The company offers in-home and in-center care, including primary care, therapies, meals, and transportation. Primarily funded by Medicare and Medicaid capitation, InnovAge serves frail, multi-condition seniors across 20 centers in six U.S. states.
Source External provider costs were $449.8 million in fiscal year 2026, representing a significant portion of total costs, primarily driven by nursing facility and assisted living utilization and unit costs.
Confidence: high
Source Salaries, wages, and benefits are a primary driver of 'Cost of care' and other operating expenses, with mentions of 'higher wage rates' impacting various departments.
Confidence: medium
Source Pharmacy expenses were a component of external provider costs, and now 'third-party fees and shipping costs associated with in-house pharmacy services' are part of cost of care.
Confidence: medium
Source 'Higher fleet costs, inclusive of contract transportation' are a component of cost of care, and transportation is described as 'fundamental to PACE and extraordinarily complex operationally'.
Confidence: medium
Source 'Supplies and administrative costs' are mentioned as increasing within cost of care.
Confidence: low
Source Investments in systems like Epic, Oracle, and Salesforce, and 'software license fees' are noted, along with significant AI investments for operational efficiency.
Confidence: low
Metric/field Effective Growth Rate for Medicare Advantage (National Average)
Cadence annual
Why it matters Medicare capitation rates are a primary revenue driver for InnovAge, and the overall MA growth rate influences PACE rate adjustments and the broader reimbursement environment.
Signal to watch Higher growth rates signal stronger revenue support; lower rates indicate potential top-line pressure.
Confidence: high
Metric/field Total State Government Tax Revenue, All States (Seasonally Adjusted)
Cadence quarterly
Why it matters State fiscal health directly impacts Medicaid budgets and, consequently, the Medicaid capitation rates InnovAge receives, especially in key states like California and Colorado.
Signal to watch Increasing state tax revenue suggests healthier state budgets, potentially leading to more favorable Medicaid rate environments.
Confidence: high
Metric/field Employment Cost Index: Wages and Salaries: Private Industry: Health Care and Social Assistance (Series ID: CIU2020000000000I)
Cadence quarterly
Why it matters Labor costs, including salaries, wages, and benefits, are a significant component of InnovAge's operating expenses. This index tracks wage inflation in their industry.
Signal to watch Lower growth in healthcare wages indicates better cost control potential; higher growth suggests increased pressure on margins.
Confidence: high
Metric/field Population 65 Years and Over (Series ID: POPTOT65UP)
Cadence annual
Why it matters InnovAge serves the elderly population, and the growth of this demographic segment is a fundamental driver of demand for their PACE services and long-term expansion opportunities.
Signal to watch Accelerated growth in the 65+ population signals a larger addressable market and sustained demand for elder care services.
Confidence: high
Metric/field Consumer Price Index for All Urban Consumers: Medical Care Services in U.S. City Average (Series ID: CPIMEDSL)
Cadence monthly
Why it matters General inflation in medical care services impacts InnovAge's non-labor operating costs, such as supplies, administrative expenses, and external provider costs not covered by capitation.
Signal to watch Lower inflation in medical care services indicates more stable operating costs; higher inflation can compress margins if not offset by rate increases.
Confidence: medium
Metric/field Search interest for 'PACE program' (topic)
Cadence daily
Why it matters Public awareness and interest in the PACE program can indicate potential demand for InnovAge's services and the effectiveness of broader industry advocacy efforts.
Signal to watch Increasing search interest suggests growing awareness and potential for higher enrollment.
Confidence: medium
Metric/field Total National PACE Enrollment (from latest publicly available CMS report)
Cadence quarterly
Why it matters Tracking aggregate PACE enrollment provides insight into the overall growth and health of the PACE market, which directly impacts InnovAge's operating environment and growth potential.
Signal to watch Consistent growth in national PACE enrollment indicates a healthy and expanding market for InnovAge.
Confidence: high
Metric/field Announcements related to Medi-Cal (Medicaid) rates or policy changes impacting PACE programs in California.
Cadence event_driven
Why it matters California represents a significant portion of InnovAge's census, and state-specific Medicaid rate and policy decisions directly affect revenue and operational stability.
Signal to watch Favorable policy changes or rate increases signal positive revenue impact; unfavorable changes indicate potential headwinds.
Confidence: high
Metric/field Announcements related to Health First Colorado (Medicaid) rates or policy changes impacting PACE programs in Colorado.
Cadence event_driven
Why it matters Colorado is another key market for InnovAge, and state-specific Medicaid rate and policy decisions directly affect revenue and operational stability.
Signal to watch Favorable policy changes or rate increases signal positive revenue impact; unfavorable changes indicate potential headwinds.
Confidence: high
Metric/field Job Openings: Health Care and Social Assistance (Series ID: JTS00000000HIL)
Cadence monthly
Why it matters High job openings in the healthcare sector can indicate labor shortages, which could lead to increased wage pressure and staffing challenges for InnovAge.
Signal to watch Decreasing job openings suggest an easing labor market, potentially reducing wage pressure and improving staffing availability.
Confidence: medium
Metric/field Weekly/Monthly Total Visits to InnovAge PACE Centers (aggregate across key locations)
Cadence weekly
Why it matters Foot traffic to PACE centers indicates participant engagement, utilization of in-center services, and overall operational activity, which correlates with participant satisfaction and retention.
Signal to watch Consistent or increasing foot traffic suggests strong participant engagement and center utilization.
Confidence: medium
Metric/field InnovAge Total Active Job Postings (Healthcare Support Roles, e.g., Nurses, Therapists, Aides)
Cadence weekly
Why it matters Monitoring InnovAge's job postings provides real-time insight into their hiring demand, potential staffing challenges, and expansion efforts, directly impacting operational capacity and costs.
Signal to watch Decreasing job postings or stable posting numbers suggest effective staffing or easing labor market conditions.
Confidence: high
Metric/field Average Hierarchical Condition Category (HCC) Score for InnovAge's PACE Participants (aggregate)
Cadence quarterly
Why it matters HCC scores reflect the acuity and health complexity of InnovAge's participant population. Higher scores generally lead to higher risk adjustment payments from Medicare, impacting revenue.
Signal to watch Stable or increasing average HCC scores indicate consistent or higher risk-adjusted revenue potential.
Confidence: high
Metric/field InnovAge Mobile App Average User Rating (iOS/Android) and Sentiment Analysis of Reviews
Cadence daily
Why it matters Participant satisfaction is a key pillar for InnovAge. App ratings and review sentiment can provide an early indicator of participant experience and potential for disenrollment or retention.
Signal to watch Improving app ratings and positive sentiment indicate strong participant satisfaction and potentially better retention.
Confidence: medium
Metric/field Population Aged 65+ and Dual-Eligible Seniors in InnovAge Service Areas (by county/zip code)
Cadence annual
Why it matters Detailed demographic data allows for precise market sizing and identification of growth opportunities within existing and potential new service areas, informing expansion strategies.
Signal to watch Growth in the target demographic within current or potential service areas signals strong market opportunity.
Confidence: high
InnovAge (INNV) has successfully transitioned to a growth phase, evidenced by exceptional FY2026 financial performance and strong FY2027 guidance, exceeding lon
InnovAge (INNV) has successfully transitioned to a growth phase, evidenced by exceptional FY2026 financial performance and strong FY2027 guidance, exceeding long-term margin targets. Despite a tempered FY2027 rate environment, strategic investments in AI, operational efficiency, and disciplined expansion (InnovAge 3.0) position the leading PACE provider for sustainable growth and long-term value creation. (Updated: 2026-09-10)
InnovAge delivered exceptional fiscal 2026 results, with adjusted EBITDA increasing approximately 175% year-over-year to $94.6 million and achieving a 9.6% margin, ahead of its 10%+ long-term target. The company projects strong fiscal 2027 adjusted EBITDA of $105 million to $115 million, demonstrating increasing business durability and effective operational management despite anticipated rate pressures.
The company is strategically entering "InnovAge 3.0," focusing on scaling its PACE platform by maximizing existing center capacity, pursuing disciplined M&A, and engaging policymakers to expand the PACE model. Strong federal interest and evidence supporting PACE's superior outcomes (fewer hospitalizations, lower mortality) for complex seniors create significant long-term growth opportunities, including serving Medicare-only populations.
InnovAge is making substantial investments in technology and AI to enhance clinical decision-making, participant experience, and operational efficiency. Successful pilots of AI-enabled physician consultation and medication optimization tools, alongside a new COO focused on operational consistency, are expected to drive better outcomes, reduce utilization, and improve cost management across its distributed network.
InnovAge faces a tempered rate environment for fiscal year 2027, with Medicare rates projected to increase only 1.5% to 2.0% and Medicaid rates in the low single digits. Significant uncertainty remains regarding final Medicaid rates in key states like California and Colorado (70% of census) due to state fiscal pressures, potentially leading to top-line pressure and margin compression if cost trends outpace rate growth.
The company's "InnovAge 3.0" growth strategy, involving evaluation of de novo markets, M&A, joint ventures, and scaling new AI technologies, introduces execution risk. Successfully integrating acquisitions, achieving desired returns on capital, and effectively deploying complex AI solutions across a multi-site operation require robust management and could face unforeseen challenges, delays, or slower-than-expected returns.
While census growth is generally predictable, the company acknowledges seasonal "softness" in the third quarter due to competition during open enrollment periods. This recurring competitive pressure, coupled with the inherent complexity of enrolling eligible seniors and managing retention, could pose ongoing challenges to consistently achieving ambitious census growth targets and impact overall revenue trajectory.
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| Progress on Strategic Growth Initiatives (M&A and Policy Modernization) | Strategic M&A and policy changes to expand PACE eligibility or simplify enrollment are key drivers for long-term growth and market expansion, especially as the company enters its 'InnovAge 3.0' phase. | Announcements of new PACE program acquisitions, joint ventures, or specific legislative/regulatory changes at the federal or state level that simplify PACE enrollment, expand eligibility, or ease market entry. | Bullish: Announcement of a new PACE acquisition, a significant joint venture, or a specific federal/state policy change that materially expands the addressable market or simplifies operations. Bearish: Lack of progress on M&A or policy fronts over multiple quarters, indicating slower-than-expected expansion. | InnovAge press releases, SEC filings, earnings call transcripts, National PACE Association news, CMS announcements. | National PACE Association website for policy updates, state legislative tracking websites for healthcare bills. | PitchBook/Crunchbase: M&A activity in the PACE/senior care sector; FiscalNote: Legislative tracking for healthcare policy |
| Final FY2027 Medicaid Rate Announcements from California and Colorado | Medicaid rates from key states like California and Colorado (representing ~70% of census) are critical for revenue and profitability, especially given current state fiscal pressures and the 'low single-digit' guidance. | Official announcements from California and Colorado state Medicaid agencies regarding final capitation rates for PACE programs for FY2027. | Bullish: Medicaid rate increases in California and Colorado exceeding 'low single-digits' (e.g., >3%). Bearish: Medicaid rate increases in California or Colorado falling below 1.5% or significant delays in finalization. | InnovAge quarterly earnings reports and conference call transcripts, official state Medicaid websites (e.g., California Department of Health Care Services, Colorado Department of Health Care Policy & Financing). Rates for these states are not yet finalized as of the transcript date. | State government budget documents, local news reports on state fiscal health and Medicaid funding. | |
| Quarterly Participant Census Growth and FY2027 Ending Census Guidance Achievement | Participant census directly drives revenue and indicates the company's ability to execute its growth strategy, especially in a tempered rate environment. Consistent growth validates the PACE model's demand and operational efficiency. | Sequential participant growth quarter-over-quarter and progress towards the FY2027 ending census guidance of 8,625 to 8,850 participants. Also, monitor member months, with FY2027 guidance of 101,000 to 102,500. | Bullish: Sequential participant growth exceeding 0.5% and achieving the high end of FY2027 census guidance (8,850 participants). Bearish: Sequential participant growth below 0.4% or missing the low end of FY2027 census guidance (8,625 participants). | InnovAge quarterly earnings reports and conference call transcripts. Next earnings call for Q1 FY2027 (September quarter) will provide the first update. | State PACE program enrollment data (if publicly available by state), local news articles on senior care demand. | Placer.ai: InnovAge center foot traffic % change YoY; Thinknum: InnovAge job postings for care staff 30-day growth |
| Quantifiable Impact of AI-Enabled Clinical Decision Support and Operational Tools | AI investments are crucial for improving care quality, participant experience, and operational efficiency, which can mitigate rate pressures and drive margin expansion in the 'InnovAge 3.0' strategy. | Management commentary on specific, quantifiable results from AI pilots (e.g., reduction in external specialist referrals, medication optimization impact, improvements in scheduling/transportation efficiency, reduction in administrative burden). | Bullish: Announcement of quantifiable improvements (e.g., X% reduction in external specialist referrals, Y% improvement in scheduling efficiency) leading to broader rollout and clear economic benefits. Bearish: Delays in scaling AI capabilities, lack of quantifiable positive impact, or significant cost overruns. | InnovAge quarterly earnings calls and investor presentations. | Academic papers or industry reports on AI in geriatric care or PACE models. | |
| Final FY2027 Medicare Rate Increase and V28 Risk Adjustment Impact | Medicare rates are a significant revenue component. The final rate and the impact of the V28 risk adjustment model transition directly affect top-line growth and overall profitability. | Official CMS announcements regarding the final Medicare rate increases for PACE programs for FY2027, particularly the net rate increase after adjusting for the 50-50 blend of V22 and V28 payment models. | Bullish: Final net Medicare rate increase for PACE exceeding 2.0% for FY2027. Bearish: Final net Medicare rate increase for PACE falling below 1.5% for FY2027. | CMS (Centers for Medicare & Medicaid Services) official announcements, InnovAge SEC filings (10-K, 10-Q), and earnings call transcripts. Medicare rates are typically updated each January. | CMS.gov: Medicare payment policy updates, National PACE Association (NPA) policy briefs. |
Participant Census directly measures the number of seniors served, indicating the company's reach and demand for its PACE model. Growth in this metric drives fu
| Key reported metrics | ||
|---|---|---|
| Metric | Last period | Why it matters |
| Participant Census | 8,230 participants (6.3% y/y growth, 2.2% sequential growth) | Participant Census directly measures the number of seniors served, indicating the company's reach and demand for its PACE model. Growth in this metric drives future revenue and operational scale. |
| Adjusted EBITDA | $94.6 million (174.2% y/y growth) for FY2026; Projected FY2027 Adjusted EBITDA of $105 million to $115 million | Adjusted EBITDA is a critical measure of operational profitability and efficiency, indicating how well the company manages costs relative to revenue. It's a focus for investors assessing financial health and margin expansion. |
| Total Revenue | $989.7 million (15.9% y/y growth) for FY2026; Projected FY2027 revenue of $1.05 billion to $1.085 billion (6.1% to 9.6% y/y growth) | This is a fundamental income statement metric reflecting the company's top-line growth, driven by participant enrollment and capitation rates. It's a key indicator of market penetration and overall business expansion. |
| Key reported metrics | Rerating thresholds | Earnings results | ||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Last period | Why it matters | What's needed for rerating | Rerating context | Earnings date | Actual reported | Hit target? | Notes |
| Participant Census | 6.9% | Participant Census directly measures the number of seniors served, indicating the company's reach and the underlying demand for its PACE model. Growth in this metric drives future revenue and operational scale. | InnovAge Holding Corp. (INNV) needs to report a Participant Census of at least 8,100 participants for the fiscal year ending June 30, 2026, which is the high end of its current guidance. This would also represent sequential participant growth exceeding 0.5% from the 8,050 participants reported at the end of Q3 FY2026. | Hitting the high end of the Participant Census guidance demonstrates strong operational execution and increasing demand for InnovAge's PACE model. This growth is crucial for driving future revenue and reinforces the company's transition to a growth phase, signaling its ability to expand its participant base and navigate anticipated rate pressures. | 8,230 participants (6.3% y/y growth, 2.2% sequential growth) | Yes | InnovAge reported an ending census of 8,230 participants for fiscal year 2026, exceeding the high end of its guidance of 8,100 participants. Sequential growth was 2.2%, well above the 0.5% threshold. This demonstrates strong operational execution and demand for the PACE model. | |
| Adjusted EBITDA | 182.4% | Adjusted EBITDA is a critical measure of operational profitability, indicating the company's efficiency in managing costs relative to its revenue. It is a focus for investors assessing financial health, with guidance also raised. | InnovAge Holding Corp. (INNV) needs to report a full-year fiscal year 2026 Adjusted EBITDA exceeding $90 million, ideally reaching at least $94.5 million (a 5% beat on the high end of current guidance). This must be accompanied by an unexpectedly optimistic outlook for fiscal year 2027, demonstrating that the company's AI investments and strategic growth initiatives are effectively mitigating anticipated rate pressures and driving stronger participant growth (sequential growth exceeding 0.5% and achieving the high end of FY2026 census guidance of 8,100 participants). | Exceeding the high end of its raised FY2026 Adjusted EBITDA guidance would signal robust operational execution and validate the company's turnaround efforts, despite a challenging rate environment. A strong FY2027 outlook, driven by successful AI integration and sustained participant growth, would demonstrate the durability of the PACE model and InnovAge's ability to expand margins and market share, thus justifying a higher valuation and strengthening the long-term investment thesis. | $94.6 million (174.2% y/y growth) for FY2026; Projected FY2027 Adjusted EBITDA of $105 million to $115 million | Yes | InnovAge reported a full-year fiscal 2026 Adjusted EBITDA of $94.6 million, exceeding both the $90 million target and the ideal $94.5 million (5% beat on the high end of prior guidance). The fiscal 2027 Adjusted EBITDA guidance of $105 million to $115 million represents an optimistic outlook, and the participant growth conditions were also met. | |
| Total Revenue | 15.5% | Total Revenue reflects the company's ability to grow its top line through increased enrollment and capitation rates. It is a key indicator of market penetration and overall business expansion, with management raising full-year guidance. | For the full fiscal year 2026, InnovAge Holding Corp. needs to report Total Revenue exceeding the high end of its raised guidance, which is $975 million. Furthermore, for the upcoming fiscal year 2027, the company needs to project a Total Revenue growth rate of at least 10% year-over-year, demonstrating successful navigation of the anticipated tempered rate environment and effective execution of strategic growth initiatives. | Exceeding the raised FY2026 guidance signals strong operational execution and robust demand for InnovAge's PACE model, validating its growth phase. A double-digit FY2027 revenue growth outlook, despite anticipated rate pressures, would demonstrate the company's ability to drive participant growth and leverage efficiency gains from AI, reinforcing the long-term investment thesis and potentially leading to a higher valuation multiple. | $989.7 million (15.9% y/y growth) for FY2026; Projected FY2027 revenue of $1.05 billion to $1.085 billion (6.1% to 9.6% y/y growth) | Partially | InnovAge's total revenue for fiscal year 2026 was $989.7 million, exceeding the high end of the raised guidance of $975 million. However, the projected total revenue growth rate for fiscal year 2027, ranging from 6.1% to 9.6%, did not meet the rerating trigger of at least 10% year-over-year growth. | |
Will InnovAge's fiscal year 2027 Medicaid and Medicare rate increases align with management's 'tempered' outlook, and how will this impact revenue guidance for
Will InnovAge's fiscal year 2027 Medicaid and Medicare rate increases align with management's 'tempered' outlook, and how will this impact revenue guidance for the upcoming fiscal year?
Can InnovAge's AI-supported clinical and operational efficiency initiatives effectively mitigate the anticipated fiscal year 2027 rate pressures and maintain consistent margins?
How much progress will InnovAge demonstrate in executing its strategic growth initiatives, including acquisitions, joint ventures, and policy modernization, to expand its PACE model and participant base?
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 3 Things Management Is Most Focused On1. **Scaling capabilities and capitalizing on growth opportunities (InnovAge 3.0)**: Management is focused on entering 'InnovAge 3.0,' which involves scaling the company's capabilities and capitalizing on market opportunities. This includes growing census within existing centers, expanding their capacity, and actively evaluating de novo markets, M&A opportunities, joint ventures, and other partnership models to expand their reach over time. 2. **Investing in technology and AI**: The company is making substantial investments in technology and AI to improve clinical decision-making, productivity, and the participant experience. Specific initiatives include enhancing participant 360, omnichannel communication, optimizing Epic EMR use, and developing AI-enabled physician decision support and medication optimization tools. 3. **Maintaining quality of care and compliance while driving operational efficiency**: Quality of care and compliance remain non-negotiable foundations for the company. Management is focused on demonstrating the increasing durability of the business by growing enrollment, improving retention, tightening the management of utilization and total cost of care, and reducing variation across centers through technology and AI for more efficient and effective operations. | Call Takeaway & ToneThe overall takeaway of the call is that InnovAge delivered strong fiscal 2026 results, demonstrating improved operational durability and exceeding expectations for Adjusted EBITDA. The company is confidently transitioning into 'InnovAge 3.0,' a strategic phase focused on scaling capabilities, expanding growth within existing centers, and pursuing disciplined M&A/partnerships. Significant investments in technology and AI are planned to enhance care, participant experience, and operational efficiency. While fiscal 2027 is anticipated to have a more tempered rate environment, management expressed confidence in driving continued earnings growth through execution, utilization management, and operational efficiencies. The tone was **optimistic and confident** regarding the company's operational improvements and future growth strategy, but **measured and realistic** about the anticipated rate environment for fiscal 2027. | Prior Quarter'S Y/Y Growth By SegmentFor the fiscal third quarter ended March 31, 2026, total revenues (Capitated payments for PACE participants) increased approximately 15.5% compared to the third quarter of fiscal year 2025. | 3 Things Analysts Most Pressed On (And Mgmt Responses)1. **2027 Rate Environment and PMPM Assumptions**: Analysts inquired about the expected changes in Medicare and Medicaid rates for fiscal year 2027, particularly the impact of the V28 risk adjustment model and state-level negotiations, and how these factors were incorporated into per member per month (PMPM) assumptions. **Management Response**: Ben Adams explained the Medicare rate calculation, including the transition to a 50-50 blend of V22 and V28 payment models and the favorable impact of dementia coding for PACE plans. He noted that California and Colorado Medicaid rates are not yet finalized, but the company has incorporated responsible assumptions, expecting a manageable but less robust rate environment than fiscal year 2026. 2. **Strategic Growth Priorities (Existing vs. New Centers/M&A)**: Analysts questioned how management prioritizes filling existing center capacity versus pursuing new growth avenues like de novos, M&A, or joint ventures, and sought an update on the M&A pipeline. **Management Response**: Patrick Blair emphasized that the primary focus remains on maximizing capacity within existing centers and creating more operational capacity. He stated a high bar for de novos but expressed greater interest in strategic M&A opportunities, citing the successful integration of Crenshaw. He highlighted the company's strong cash flow and balance sheet position for disciplined M&A. 3. **Policy Discussions with CMS (Reducing Barriers & Adjacent Populations)**: Analysts inquired about the ongoing policy discussions with CMS regarding reducing barriers to PACE growth and potentially applying PACE capabilities to adjacent senior populations. **Management Response**: Patrick Blair explained that barriers primarily revolve around simplifying PACE enrollment and making it easier to expand into new markets (awareness, eligibility, program requirements, development timelines). For adjacent populations, he discussed Medicare-only adults with functional impairment who are upstream of PACE, suggesting a PACE-inspired model could alter their trajectory towards institutional care, reducing acute/post-acute utilization and lowering the total cost of care. | Revenue SegmentsFor the fiscal year 2026, total revenues (primarily Capitated payments for PACE participants) increased by 15.9% to $989.7 million. For the fourth quarter of fiscal year 2026, total revenues increased 18.3% year over year to $262.0 million. |
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 3 Things Management Is Most Focused On1. **Reinvesting in the business**: Management is focused on continued investment in clinical teams, advancing their technology platform (including early applications of AI to improve care coordination and participant experience), and strengthening how they measure and manage quality. This is viewed as essential for long-term sustainable performance and directly benefiting participants. 2. **Strategic Growth**: The company is taking a more forward-looking view on growth, aiming to fill existing centers, strengthen sales capabilities, expand through new channels and partnerships, and evaluate broader growth alternatives such as acquisitions, joint ventures, partnerships, or participation in new programs and demonstration models. 3. **Navigating the Rate Environment**: Management is focused on managing through a potentially more challenging rate environment in fiscal year 2027, with anticipated lower Medicaid rate increases and a modest Medicare rate increase. They plan to address this through improved cost discipline, operating visibility, and continued execution, emphasizing the durability of their PACE model. | Call Takeaway & ToneThe overall takeaway of the call is that InnovAge delivered solid fiscal Q3 2026 results, demonstrating consistent performance and operational improvements, which led to raised fiscal year 2026 guidance. The tone was **cautiously optimistic**. Management highlighted the company's transition from a stabilization phase to a strategic growth phase, enabled by its strong foundation and cash flow generation. However, a note of caution was introduced regarding the anticipated more tempered rate environment for fiscal 2027, particularly with Medicaid budget pressures. The company's strategic focus on leveraging technology like AI to enhance efficiency and quality, alongside disciplined growth initiatives, emerged as key themes for navigating future challenges and driving long-term value. | Prior Quarter'S Y/Y Growth By SegmentIn the fiscal second quarter of 2026 (ended December 31, 2025), total revenues increased approximately 14.7% compared to the second quarter of fiscal year 2025. | 3 Things Analysts Most Pressed On (And Mgmt Responses)1. **2027 Rate Environment and Cost Management**: Analysts inquired about the expected changes in Medicaid rate increases for 2027 compared to prior periods and management's confidence in maintaining cost growth. **Management Response**: Patrick Blair stated that 2027 rates are still evolving due to a complex fiscal backdrop for states, which is typical for a state-partnered model. He emphasized staying closely aligned with state partners, delivering high-quality care, and operating efficiently. He expressed confidence in managing cost trends, citing ongoing AI-supported initiatives in clinical workflows, scheduling, transportation, and care coordination to improve efficiency and participant experience. 2. **Sustainability of Q3 Revenue Upside**: Analysts asked about the sustainability of the better-than-expected Medicaid rates and favorable Medicare risk scores seen in Q3. **Management Response**: Ben Adams confirmed that the step-up in Medicaid rates (particularly in California) and risk scores in the second half of fiscal 2026 were positive. He believes the improvement in risk scores ought to be durable, assuming no significant change in population mix, but noted that the Medicaid rate outlook for 2027 is expected to be more tempered. 3. **Go-Forward Growth Strategy and Growth vs. Profitability Trade-off**: Analysts pressed on the company's new strategic flexibility for growth (M&A, JVs, new programs) and how management would balance growth versus profitability in a potentially more challenging rate environment. **Management Response**: Patrick Blair highlighted evaluating M&A (especially for smaller, struggling PACE programs), hospital joint ventures, and policy modernization to simplify enrollment. He also mentioned exploring 'PACE-inspired adjacencies' for seniors not currently eligible for PACE. Regarding the trade-off, management stated that investing heavily in quality to drive growth, improving the participant experience, and focusing on sales and marketing to increase gross enrollment and reduce disenrollment are priorities. They indicated that investing in growth while maintaining consistent margins is currently more of a priority than expanding margins. | Revenue SegmentsTotal revenues increased 15.5% compared to the third quarter of fiscal year 2025. This growth was driven by higher capitation rates, which reflect annual Medicaid and Medicare rate increases and a lower revenue reserve, as well as growth in member months, primarily from enrollment expansion across California, Colorado, and Florida centers. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| About Expanding Eligible MarketInnovAge is entering InnovAge 3.0, focused on scaling capabilities and capitalizing on opportunities, including growing census within its existing footprint, expanding center capacity, and diversifying channels for eligible seniors to access PACE. The company is actively evaluating de novo markets, M&A opportunities, joint ventures, and other partnership models to expand its reach. InnovAge is also engaging with policymakers to expand PACE and potentially apply its model more broadly, addressing barriers to enrollment and expansion. There's a recognized opportunity to serve a large and growing population of Medicare-only adults with functional impairment who are currently upstream of PACE and on a trajectory toward institutional care. The company's focus remains on maximizing capacity in existing centers, while M&A is seen as potentially delivering a better return on invested capital than de novos over a 3- to 5-year period. | About CompetitionThe company notes that the third quarter typically sees some softness in enrollment, which is related to competition associated with open enrollment during that period. InnovAge believes that a stronger operating platform provides a competitive advantage when exploring new growth opportunities. | About The Broader IndustryThe rate environment developed more favorably than anticipated in fiscal 2026. There is a strong level of federal interest in the PACE program, developing along two parallel tracks: strengthening the existing PACE program by understanding and removing barriers to growth and adoption, and exploring whether PACE capabilities could apply to additional senior populations. A study by HHS' Office of the Assistant Secretary for Planning and Evaluation found that PACE participants experienced fewer hospitalizations, emergency department visits, and lower mortality than comparable beneficiaries in non-integrated Medicare Advantage plans. The combination of growing evidence supporting the PACE model, an aging population, increasing pressure on institutional care, and high engagement from federal policymakers marks a key moment for PACE. State government partners are navigating fiscal pressures, which could impact PACE reimbursement rates, particularly in California and Colorado, which represent approximately 70% of InnovAge's census. For Medicare, the company expects a net rate increase of approximately 1.5% to 2.0%, adjusted for the transition to a 50-50 blend of the V22 and V28 risk adjustment models, with V28 treating dementia coding favorably, which benefits PACE plans due to the high prevalence of dementia among participants. | Where Things Are HeadedInnovAge is entering 'InnovAge 3.0,' focusing on scaling its capabilities and capitalizing on opportunities, aiming to build a sophisticated value-based care platform to serve more seniors sustainably. The company plans to invest in technology and AI to improve clinical decision-making, productivity, and participant experience. For fiscal 2027, InnovAge is targeting an ending census of 8,625 to 8,850 participants (5% to 7.5% growth), total revenue of $1.05 billion to $1.085 billion, and adjusted EBITDA of $105 million to $115 million. Fiscal 2027 is expected to demonstrate the increasing durability of the business, with earnings growth dependent on execution, including enrollment growth, retention, utilization management, and leveraging technology and AI for efficiency. The company anticipates a more challenging rate environment in fiscal 2027 and will prioritize disciplined margin management, aiming for long-term sustainable margins of 10% plus. De novo losses for fiscal 2027 are projected to be between $0.4 million and $0.8 million. | Updates On ThemeSenior | Broader Themes EmergingArtificial intelligence (AI) is a significant emerging theme, with InnovAge pragmatically investing in AI to improve care, participant experience, reduce administrative burden, and operate centers more efficiently. Specific AI use cases include AI-enabled physician decision support, an AI-enabled consultation agent for frailty and geriatric care, a medication optimization agent, and AI for scheduling and transportation optimization. | Bullish-Leaning Quotes (Short)Fiscal 2026 was an exceptional year for InnovAge and a key milestone in the transformation of the company. Adjusted EBITDA increased approximately 175% compared with fiscal 2025, and we believe we are ahead of schedule to achieve our 10-plus percent long-term adjusted EBITDA margin target. We're excited about fiscal 2027 and increasingly confident in the longer-term opportunity ahead of the company. The business now is producing strong cash flows and cash conversion, and we've got a lot of opportunity on the balance sheet. | Bearish-Leaning Quotes (Short)The rate environment also developed somewhat more favorably than we anticipated during the year, which contributed to our performance. We will not have all the same rate increases that contributed to fiscal 2026. We are expecting a Medicare rate increase of 1.5% to 2% and low single-digit rate increases for Medicaid. The rates aren't going to be as robust as they were last year. It's the third quarter where we typically see some softness, and that's related to some of the competition associated with open enrollment during that period of time. | HiringJen Browne joined as President and Chief Operating Officer earlier this summer, significantly increasing leadership capacity. Sales and marketing expenses increased due to increased headcount and wage rates to support growth. Corporate, general and administrative expenses increased due to higher employee compensation and benefits expense, organizational restructuring activities, executive severance, increased headcount, and higher wage rates. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| About Expanding Eligible MarketInnovAge is evaluating a broader set of potential growth alternatives to expand its model to more seniors, including acquisitions, joint ventures, partnerships, or participation in new programs and demonstration models. The company sees meaningful opportunity within its existing footprint by filling current centers, strengthening sales capabilities, and expanding reach through new channels and partnerships. They believe the PACE model can be adapted to serve seniors not currently eligible and are working with industry peers and regulators on policy modernization to simplify enrollment and expand the program. | About CompetitionThe company highlights the strong belief in the PACE value proposition among state partners, noting its alignment with states' goals for caring for high-needs populations. | About The Broader IndustryThe final 2027 Medicare rate notice was more favorable than initially proposed, particularly for Medicare Advantage plans, but the benefit for PACE is more limited due to different rate setting frameworks and population complexity. Early indications suggest increasing budget pressures from state Medicaid partners, potentially leading to lower rate increases in fiscal year 2027 compared to historical trends. The company views this as normal cycle variability, expecting the rate environment to normalize over time, as rates have historically kept pace with the underlying cost of care. AI is emerging as a significant enabler in the healthcare industry, with InnovAge investing in its application to improve care coordination, participant experience, and operational efficiency. | Where Things Are HeadedInnovAge is entering a new phase focused on expanding access to its model and serving more seniors. The company is raising its fiscal year 2026 guidance, now expecting revenue in the range of $950 million to $975 million and adjusted EBITDA between $85 million and $90 million. While fiscal year 2027 is anticipated to have a more tempered rate environment, potentially leading to top-line pressure, the company expects the rate environment to normalize over time and is confident in its ability to manage through this period. Strategically, the company prioritizes investing in growth while maintaining consistent margins, rather than expanding margins further at this point. | Updates On ThemeInnovAge, | Broader Themes EmergingAI is a broader theme emerging across industries, with InnovAge investing heavily in its application to improve care coordination, participant experience, and operational efficiency within their model. | Bullish-Leaning Quotes (Short)We delivered a solid third quarter and continue to see steady momentum across the business. We are once again raising our fiscal year 2026 guidance for revenue and adjusted EBITDA. Overall, our performance continues to show steady year-over-year improvement across key operational and clinical metrics. The business is operating from a position of strength. | Bearish-Leaning Quotes (Short)we are planning for a more tempered environment in fiscal 2027. we expect Medicare rates to increase approximately 1.5% to 2% in fiscal year 2027, which is more modest. On the Medicaid side, we're beginning to see early indications from our state partners that budget pressures are increasing. cost trends may outpace rate growth and margins can tighten without other offsetting improvements. | HiringThe company experienced a net increase in salaries, wages, and benefits due to higher wage rates, partially offset by reduced headcount. They are adding new members to the sales and marketing team and are exploring new channel partnerships. AI tools are being designed to support, not replace, clinical judgment. |
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| INNV_e340a1fe | Effective January 1 | 2027-01-01 | 2027-01-01 | CMS transition to a 50-50 blend of the V22 and V28 payment models for Medicare rates. | This transition impacts Medicare reimbursement rates for PACE programs, with InnovAge expecting a net rate increase of 1.5% to 2.0%, partially driven by favorable treatment of dementia coding under V28, directly affecting revenue and profitability. | Ticker | 2026-09-08 | earnings_transcript |
| INNV_cdd51ecb | on our fourth quarter and fiscal year earnings call in early September | 2026-09-01 | 2026-09-15 | InnovAge to provide detailed fiscal year 2027 outlook, including Medicare and Medicaid rates. | This will provide crucial information on the company's expected revenue and margin environment for the upcoming fiscal year, which management has indicated will be more challenging due to rate pressures. It will inform investors about the financial trajectory of the company for FY27. | Ticker | 2026-05-05 | earnings_transcript |
| INNV_10efbece | waiting for the final public policy adjustments there to know what the net impact is going to be like | 2026-09-10 | 2026-12-31 | Finalization of Colorado Medicaid capitation rates for fiscal year 2027. | Colorado represents a significant portion of InnovAge's census (approximately 70% combined with California), and the finalization of these rates will directly impact the company's revenue and profitability for fiscal year 2027. | Ticker | 2026-09-08 | earnings_transcript |
